Slide 1

Liquid biopsy
at your hands

Our Product

RUBYnanomed has developed a precise cancer snapshot tool, the RUBYchip™ , that offers oncologists a non-invasive tool for monitoring cancer progression in real time.

Discover our innovative and revolutionary technology.

What makes the RUBYchip™  unique

Earlier diagnosis

Non-invasive analysis

Higher selectivity

Higher sensitivity

Reduced costs

No sample preparation

They trusted us to help their patients

Our Awards

Net Zero Health Systems Acceleration Program

Startup Lisboa

2024

Prémio Startup Novos Negócios

Portugal Ventures

2023

AstraZeneca Sustainability Summit

2023

Prémio de Inovação / Melhores de Portugal Tecnologico

Prémio Exame Informática

2021

Health Technology Tech Winner

Elevator Pitch Competition (EPiC) 2020 by ​Hong Kong Science and Technology Parks Corporation (HKSTP)

2020

IP valorisation prize

IPA4SME programme, launched by the European Commission

2020

INNOV ID funding

Portugal Ventures

2020

Emerging Technologies Competition winner (health)

Royal Society of Chemistry

2019

Advanced Materials Competition (AdMaCom) First Prize

by Innovation Network for Advanced Materials (INAM)

2018

Resolve- Health

University of Porto

2017

NanoTechNorte

University of Porto

2017

StartupNano First Prize

INL

2016

Our Projects

Ongoing

BRIGHT EU

EIC Accelerator by European Innovation Council
Ongoing

BIOCELLPHE

EU Horizon 2020
Finished

BRIGHT PT

AVISO 18 Norte 2020
Finished

PERSIST

EU Horizon 2020
Finished

CTC-OncoDynamics

Caixa Impulse Consolidate by LA CAIXA Foundation

Follow us On LinkedIn

RUBYnanomed
22 de April, 2024

Thanks to Startup Lisboa and NetZero program managers and mentors, to fellow startups , to the juri experts and to AstraZeneca for their support to the RUBYnanomed team.

RUBYnanomed
22 de April, 2024

We were honoured to receive the second price at the international #AstraZenecaSustainabilitySummit.

RUBYnanomed
19 de December, 2023

We are thankful to our shareholder Portugal Ventures to have recognised our trajectory during 2023 in the category of “New Businesses”.